FDA Grants Orphan Drug Status

This is a news story, published by Yahoo Finance, that relates primarily to Riliprubart news.

Riliprubart news

For more Riliprubart news, you can click here:

more Riliprubart news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

pharmaceutical capsules

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest FDA news, Sanofi news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

orphan drug designation

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

•

Health

FDA grants orphan drug designation to Sanofi's Riliprubart

Summary

Nutrition label

64% Informative

Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for treating antibody-mediated rejection in solid organ transplantation.

This is a significant milestone for Sanofi as it provides benefits including tax credits, user fee waivers, and market exclusivity upon approval.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech